Psilocybin Study

The safety and efficacy of psilocybin in participants with treatment-resistant depression (P-TRD). 

For more information on this trial for clinicians click HERE.  For non-clinicians click HERE.

For further information about the trial from the sponsor, go to the COMPASS website:

Presentation given by James Rucker at the PAX-BD Launch meeting in London on the 17th September 2018  -'Back to the Future Psilocybin Trials in Treatment Resistant Depression in the UK'